The proven clinical efficacy of passively transferred hyperconformational components. This antibody was evaluated for its ability to mediate both pre-and postexposure prophylaxis immune globulins in prevention of viral disease [1 -3] has led to the evaluation of passive immunoprophylaxis of human of HIV-1 LAI infection in SCID mice reconstituted with human peripheral blood lymphocytes (Hu-PBL-SCID) mice. immunodeficiency virus type 1 (HIV-1) infection. Clinical trials have evaluated polyclonal HIV immune globulins (HIVIG) or neutralizing monoclonal antibodies (MAbs) in persons with advanced disease [4 -6] . It seems likely, however, that passive Materials and Methods immunization against HIV will hold greatest potential for the shown to protect chimpanzees against experimental intravenous
Immunoglobulin preparations. The human neutralizing MAb challenge when administered either before [7] or shortly after 694/98-D was purified from hybridoma culture supernatant by [8] virus exposure.
protein A affinity chromatography as described [11] . The resulting
The human MAb 694/98-D mediates potent neutralization protein solutions contained between 4 and 8 mg/mL IgG. The characteristics and mode of preparation of HIVIG have been preof HIV-1 LAI in vitro [9] . The linear V3 core epitope recognized viously reported [12] . The preparation is virus-sterilized and conby 694/98-D maps to the conserved GRAF motif at the tip tains 5% IgG formulated for intravenous application. A control of the V3 loop. However, the antibody binds with 1 -3 orders intravenous immunoglobulin preparation (IVIG), lacking detectof magnitude greater affinity to native gp120 than to linear able anti-HIV antibody by ELISA, was obtained from the Melville peptides [10] , suggesting that the epitope may also possess Biologics Division of the New York Blood Center.
Virus stocks. A seed stock of HTLV-1 IIIB (HIV-1 LAI ) was provided courtesy of R. Gallo (National Cancer Institute, Bethesda, MD; currently University of Maryland, Institute of Human VirolReceived 2 July 1997; revised 30 October 1997. ogy, Baltimore). A stock of HIV-1 LAI adapted for growth on human Animals were housed under conditions that met or exceeded the requirements peripheral blood lymphocytes (PBL) was prepared by inoculation of the NIH Guide for Care of Laboratory Animals.
of a CEM cell-grown virus supernatant onto phytohemagglutinin by intraperitoneal inoculation of Hu-PBL-SCID mice with serial TCID 50 of virus stock. After 5 days of culture, the cells were half-log dilutions of virus, using an average of 10 mice/dilution. pelleted, and total nucleic acids were extracted by the Isoquick Infection was assessed 3 weeks after virus inoculation as described procedure (Microprobe, Bothell, WA). A 310-bp DNA fragment below, and MID 50 s were determined from the titration curve.
covering the hypervariable region of the HIV-1 V3 loop and flankIn vitro assays for virus infectivity and neutralization. All in ing sequences was amplified from extracted nucleic acids by use vitro assays for virus infectivity and neutralization were done with of the primer pairs described by Epstein et al. [14] : forward primer, human PBL target cells. Cryopreserved human PBL were thawed 5-ATAAGCTTGCAGTCTAGCAGAAGAAGA-3; reverse and activated by incubation with PHA (1 mg/mL; Gibco BRL, primer, 5-ATGAATTCTGGGTCCCCTCCTGAGGA-3. Grand Island, NY) in RPMI 1640 medium containing 20% heat-PCR reactions were done essentially as described by Epstein et inactivated fetal calf serum (Hyclone, Logan, UT), L-glutamine, al. [14] , and products were cloned (TA Cloning System; Inpenicillin, and streptomycin. After 3 days of incubation, the cells vitrogen, San Diego). PCR product ligations to cloning vector were washed and resuspended at 3 1 10 6 /mL in the above medium pCRII and subsequent transfections into E. coli were done acsupplemented with 20 U/mL recombinant human interleukin-2 cording to the kit manufacturer's instructions, except that PCR (Boehringer Mannheim, Indianapolis) (complete medium). Virus products were purified by elution from 1% Nusieve agarose (FMC infectivity was assayed by incubation of serial log or half-log Bioproducts, Rockland, ME) gels before ligation. Ampicillin-resisdilutions of virus stock (4-6 replicate cultures/dilution) with 1.5 tant bacterial colonies were inoculated into Luria broth, and DNA 1 10 5 PHA-stimulated PBL in 150 mL of complete medium. Culwas extracted from 1.5 mL of overnight culture by use of the tures were fed every 2-3 days, and supernatants were harvested boiling miniprep method [15] . The insert sequence of purified for end-point determination by p55 antigen ELISA at 14 days [13] .
plasmid DNA was determined along each DNA strand by use of Polyvinyl assay plates (Costar, Durham, NC) were coated with an oligonucleotide corresponding to the plasmid T7 promoter (5-rabbit antiserum raised against recombinant Escherichia coli -de-TAATACGACTCACTATAGGG-3) and either the forward or rerived HIV p55 (gift of H. Chan, Syntex, Palo Alto, CA [10] . A set of 133 analogue septapepwas determined at 490 nm. Absorbance values greater than three tides for the GPGRAFY sequence, in which each residue was times the mean absorbance of replicate negative control culture replaced by the other 19 amino acids, was synthesized on plastic supernatants were considered to be positive for p55 antigen.
pins according to the method developed by Geysen et al. [16] . The TCID 50 s of virus were calculated by the Spearman-Karber method.
GPGRAFY sequence was derived from the V3 region of HIV-1 MN Neutralization assays were done by use of a calculated input of gp120. Supernatant of the 694/98-D hybridoma cell line containing 100 TCID 50 of pre-titered virus/culture and used the same cryopre-10 mg/mL MAb was reacted with the septapeptides, and binding served donor PBL that were used for virus titrations. Virus stocks of the MAb to the peptides was determined as previously described were titrated in parallel within each neutralization assay as de- [10] . scribed above to ensure accuracy of the input inoculum. Input Engraftment and infection of Hu-PBL-SCID mice. We have virus was incubated for 1 h at 37ЊC in 100 mL of complete medium observed a significant variation in the ability of PBL from individcontaining serial 2-fold dilutions of antibody (4-6 replicate culual donors to establish engraftment in SCID mice. PBL from pertures/dilution). PHA-stimulated PBL were then added (3 1 10 5 sons in our laboratory were therefore screened to identify optimal cells in 50 mL of complete medium). After overnight incubation, donors. Large numbers of PBL (0.5-1 1 10 10 ) were obtained from the cultures were washed four times by centrifugation and resusthese donors by cytapheresis and centrifugation over Histopaque pension in complete medium to remove input p24 and HIV anti-(Sigma, St. Louis) and cryopreserved at 1ЊC/min by use of a Biobody. After an additional 6 days of culture, an aliquot of the cool rate-controlled freezer. We have observed no significant difsupernatant was removed, and p24 antigen levels were quantitated ference in the ability of fresh or cryopreserved cells to establish by assay of an appropriate supernatant dilution in antigen-specific engraftment in SCID mice as assessed by measurement of human ELISA (Coulter, Hialeah, FL). Levels of p24 antigen in culture immunoglobulin levels in the serum of engrafted mice, cell cytosupernatants were calculated according to the kit manufacturer's metric analysis of cells recovered from the spleen and peritoneal instructions from a standard p24 protein curve included on each cavity, and susceptibility to HIV infection. SCID mice were en-ELISA plate. Percentage of inhibition of virus replication was grafted by intraperitoneal injection of 4 1 10 7 PBL in 0. 
Assessment of HIV infection in Hu-PBL-SCID mice.
Three were stored at 020ЊC until assay. Levels of 694/98-D in plasma samples obtained from non-engrafted SCID mice were determined weeks after virus inoculation, Hu-PBL-SCID mice were sacrificed by Metophane (Pitman-Moore, Mundelein, IL) inhalation and exby testing of duplicate serial 2-fold dilutions of each sample (beginning at 1/100) in the ELISA for human IgG described above, sanguination. The peritoneal cavity was washed out with 4 mL of RPMI 1640, and the spleen was removed and rinsed with RPMI except that bound immunoglobulin was detected with peroxidaseconjugated goat anti-human IgG(Fc) (Kirkegaard & Perry, Gai-1640 before being disrupted between glass microscope slides. Both spleen and peritoneal cells were washed once to remove in vivothersburg, MD), and color was developed with tetramethylbenzidine liquid substrate (Sigma), followed by absorbance determinaadministered antibody and placed into coculture for virus isolation with PHA-stimulated human PBL from the same donor used for tion at 450 nm. Levels of 694/98-D in plasma samples obtained from Hu-PBL-SCID mice were determined by ELISA for antibody SCID mouse engraftment. Duplicate 2-mL cultures contained 2 1 10 6 PHA blasts and 1-2 1 10 6 peritoneal lavage cells or 1-5 1 binding to HIV-1 proteins. Vinyl assay plates were coated with either 200 ng/well modified HIV-1 LAI V3 loop peptide CGG-RIQ-10 6 spleen cells in RPMI 1640, 20% heat-inactivated fetal calf serum, and 20 U/mL recombinant human interleukin-2 (Boehringer RGPGRAFVTIGK or 100 ng/well HIV-1 SF2 recombinant gp120 [17] (catalog no. 386; NIH AIDS Research and Reference Reagent Mannheim). Twice weekly, half of the culture supernatant was removed and replaced with fresh complete medium. Fresh PHAProgram) diluted in carbonate buffer, pH 9.6. Wells were blocked (Superblock; Pierce, Rockford, IL) for 30 min at room temperature. stimulated human PBL were added after 2 weeks of culture, and cultures were maintained for 4 weeks. At weekly intervals, harSerial 2-fold dilutions of each test sample (beginning at 1/100) were prepared in Superblock and incubated in assay plates for 2 vested culture supernatants were virus-sterilized by addition of 0.5% Triton X-100 and incubation for 1 h at 37ЊC and were assayed h at 37ЊC. After extensive washing with PBST, bound immunoglobulin was detected by incubation with peroxidase-conjugated by ELISA for HIV p55 antigens as described above. Animals were considered to be HIV-infected if virus was isolated from either goat anti-human IgG(Fc) (Kirkegaard & Perry) diluted 1/1000 in Superblock supplemented with 2% heat-inactivated normal goat spleen or peritoneal lavage cell cocultures, although in the majority of animals, both cell populations gave concordant results.
serum (Gibco BRL). Color was developed with tetramethylbenzidine liquid substrate as described above. Serum samples from Cardiac blood was collected from Hu-PBL-SCID mice at the time of sacrifice and allowed to clot at 4ЊC overnight. Serum control Hu-PBL-SCID mice, which expressed between 1 and 5 mg/mL human IgG and which received no 694/98-D, showed no samples were stored at 070ЊC until assay for human immunoglobulin levels as described below. data from the peptide-binding assay are shown.
We have observed an almost absolute correlation between the presence in serum of human IgM, levels of human IgG ú1 mg/ As shown in figure 1 , the plasma half-life of 694/98-D was mL, and susceptibility to HIV-1 infection (unpublished data). Anisimilar in both engrafted and non-engrafted animals and was mals that have õ1 mg/mL human IgG and no detectable human calculated to be Ç9 days. These pharmacokinetics compare [19] .
was determined by testing of serial plasma samples by ELISA. injected intraperitoneally with serial half-log dilutions of anti-070ЊC. These virus stocks were subsequently titrated for infectivity on PHA blast target cells and tested for susceptibility to body. Control animals were either left untreated or injected with 500 mg/kg anti-HIV -negative IVIG preparation. Two in vitro neutralization by the antibody used for passive immunization and by polyclonal HIVIG. The amount of 694/98-D hours after injection of antibody, animals were challenged by intraperitoneal inoculation of 10 MID 50 of HIV-1 LAI . Plasma required to achieve 50% neutralization of 100 TCID 50 of both the spleen-and peritoneal cell -derived virus stocks was levels of human MAb in Hu-PBL-SCID mice at the time of virus challenge were measured by ELISA and were estimated roughly 80-fold higher than that required to achieve 50% neutralization of 100 TCID 50 of the parent HIV-1 LAI inoculum. to be 156 { 11 mg/mL in mice that received 40 mg/kg 694/ 98-D. Three weeks after virus inoculation, the animals were Figure 4A shows a titration of 694/98-D against the spleen cell coculture-derived virus and the parent HIV-1 LAI stock that was sacrificed, and infection was assessed by virus isolation in cocultures of both spleen and peritoneal lavage cells. As shown used for inoculation into Hu-PBL-SCID mice. As shown in figure 4B , both virus stocks were neutralized equally well by in figure 2, 50% protective efficacy was achieved with a dose of 1.32 mg/kg 694/98-D (Ç33 mg/mouse). (table 1) . To isolate the neutralization-resistant virus(es) before or after challenge with 10 MID 50 of HIV-1 LAI . As shown in figure 3 , administration of 40 mg/kg MAb protected all mice within this apparently mixed population, the spleen-derived virus stock was cloned by limiting dilution after a brief expoagainst detectable infection when administered either before or 15 min after virus inoculation. Efficacy declined to 50% if sure to the immunizing MAb. Serial 2-fold dilutions of virus, 12 replicates/dilution, were prepared in medium containing 20 antibody administration was delayed to 1 h after virus inoculation. Protective efficacy at the 1 h postexposure time point was mg/mL 694/98-D in a volume of 100 mL. After incubation for 1 h at 37ЊC, PHA-stimulated PBL were added (3 1 10 5 cells not improved by the simultaneous injection of 694/98-D with human complement in the form of 0.2 mL of fresh-frozen in 50 mL of complete medium), and infection was allowed to proceed for 2 h at 37ЊC. The cultures were washed four times human plasma (data not shown).
Preexposure prophylaxis of HIV-1 LAI infection by MAb 694/

Isolation of a 694/98-D neutralization escape variant.
In by centrifugation and resuspension in complete medium to remove antibody. Cultures were maintained in complete methe preexposure prophylaxis experiment shown in figure 2 , both of the duplicate spleen and peritoneal cell cocultures of 1 of 6 dium without added antibody, and supernatant p24 levels were assayed after 14 days of culture. mice that received 13.2 mg/kg 694/98-D, the maximal dose of MAb that did not protect 100% of the mice, were found to be Five p24 antigen -positive cultures were selected from limiting dilutions. Total nucleic acids were extracted from these strongly positive for HIV-1 p55 antigens after 5 days of culture. Cell-free supernatants from these duplicate cocultures were cultures, DNA-based PCR for V3 loop sequences was done, and the resulting products were cloned by ligation to vector harvested at this time, pooled, aliquoted, and snap-frozen at / 9d43$$ap30 02-09-98 08:27:51 jinfa UC: J Infect pCRII and transfection into E. coli as described above. The HIV-1 LAI [20] , two non-silent nucleic acid changes were observed within the V3 loop region (A to G at position 6495 and consensus V3 loop sequence of each biologic clone was determined by sequencing of plasmids from at least 5 bacterial G to A at position 6525) encoding amino acid changes in the linear core epitope recognized by 694/98-D (alanine to clones containing inserts in either orientation in the cloning vector.
threonine) and in one flanking amino acid (serine to glycine). Figure 5 shows an alignment of the deduced V3 loop amino The consensus DNA sequences derived for all 5 biologic clones were identical. Relative to the published sequence of acid sequence of the 5 biologic clones with that of HIV-1 LAI and with that of the PBL-adapted HIV-1 LAI parent inoculum used for infection of Hu-PBL-SCID mice in these studies. The derived by PCR from proviral DNA as described above. As residues of the parent septapeptide could each be substituted to determine the amount of antibody needed for preexposure prophylaxis, 50% protection was observed with a dose of 1.32 with one of several amino acids while maintaining ú50% binding of the MAb. However, replacement of the third, fourth, mg/kg MAb, and 100% protection was observed with a dose of 40 mg/kg. These doses are within the realm of feasibility and fifth amino acids with most amino acids dramatically reduced the ability of the MAb to bind. Of particular note in this for use in humans and compare favorably with previously determined dose requirements of HIVIG for prevention of HIV-1 set of data is the replacement of the A in the fifth position with T. This substitution, the same as that noted in the escape variant infection in Hu-PBL-SCID mice: 100 to ú1000 mg/kg for 50% protection, depending on the virus isolate tested [19] . described above, resulted in õ50% binding to the substituted peptide compared with that of the parent molecule.
Recently, Gauduin et al. [21] reported on the efficacy of a murine HIV-1 -neutralizing MAb (BAT123) for both pre-and postexposure prophylaxis of HIV-1 LAI infection in Hu-PBLDiscussion SCID mice. In preexposure titrations of antibody in mice, BAT123 protected all animals against infectious challenge We have evaluated a potent HIV-1 -neutralizing human when given at a dose of §1 mg/kg; 43% protective efficacy MAb for efficacy in both pre-and postexposure prophylaxis was achieved with a dose of 0.1 mg/kg. These antibody doses of HIV-1 LAI infection in Hu-PBL-SCID mice. In an experiment are substantially lower than the doses of human MAb 694/98-D required for protection of Hu-PBL-SCID mice in the present study. However, these in vivo results are not discordant with results that may be expected on the basis of in vitro testing of these antibodies. Fifty percent in vitro neutralization of HIV-1 LAI on PBL target cells was obtained with a dose of 0.09 mg/ mL BAT123 [22] ; in the present study, 50% neutralization of HIV-1 LAI on PBL target cells was obtained with a dose of 0.6 mg/mL 694/98-D. More difficult to explain is the marked difference between 694/98-D and BAT123 in their efficacy in postexposure prophylaxis of HIV-1 LAI infection. Administration of BAT123 at a dose of 1 mg/kg was able to protect almost all Hu-PBL-SCID mice against infection when administered as late as 4 h after virus inoculation. However, surprisingly, BAT123 showed little postexposure efficacy in vitro [23] . In the present study, administration of 40 mg/kg 694/98-D protected all mice against detectable infection when given at 15 min but not at 1 h after virus inoculation. We have observed similar time constraints on postexposure prophylaxis by HIVIG [19] and with two other human neutralizing MAbs: the anti-gp41 antibody 2F5 [24] and the anti-gp120 antibody 2G12 [25] (unpublished data). As pointed out by Gaudin et al. [21] , possible explanations for differential efficacy of antibodies in postexposure prophylaxis could include differences in affinity or differences in ability to mediate antibody-dependent MAbs are reduced to low, though still inhibiting, concentrations The infectious doses of virus used for the challenge of Hu- [35] . PBL-SCID in our own studies, and in those of others [21, 22, Although the V3 loop sequence of the variant virus was not 28], are considerably higher than those likely to be encountered found among 53 sequenced PCR clones of the parent inoculum, during infection either by accidental needlestick or by materit is not possible to determine whether the variant virus arose nal-infant transmission. This is evident from the relatively low through in vivo mutation and antibody selection or through rates of virus penetrance in either of the above transmission selection of a variant already present in the parent infecting modes: õ1% and 20% -30%, respectively, in the absence of inoculum. No neutralization escape wells were seen when the therapeutic intervention. Moreover, accidental exposure in huparent inoculum was titrated in the presence of 20 mg/mL 694/ mans is likely to involve an intracutaneous route of infection, 98-D and p24 levels were assayed after 14 days (starting with which differs markedly from the intraperitoneal route used in 2000 TCID 50 /well, 4 replicates/dilution). This suggests that if these studies. A third variable is the lack of effective hostindeed the resistant variant was present in the parent inoculum, mediated cellular or humoral immunity in Hu-PBL-SCID mice.
it was present at a frequency of õ1/8000. Regardless of the Thus, time constraints for effective postexposure prophylaxis origin of the variant, however, these studies reinforce the notion of infection in humans may be quite different from those imthat passive immunization with MAbs is unlikely to succeed plied by studies in animals. In a recent chimpanzee study, we unless MAbs with different specificities are used in combinaevaluated postexposure prophylaxis of HIV-1 LAI infection by tion with one another or with HIVIG. HIVIG (unpublished data). In this study, administration of 500 mg/kg HIVIG to 2 chimpanzees either 1 or 4 h after intravenous
